Related Experiment Video

Updated: Aug 28, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell

Ying Li1, Peng Yang2, Xiao Zhou3

  • 1Respiratory Medicine, Daqing Oilfield General Hospital, Daqing, China.

Frontiers in Surgery
|September 19, 2022
PubMed
Abstract

Insights

Programmed cell death 1 (PD-1) inhibitor combined with chemotherapy shows improved outcomes for advanced non-small-cell lung cancer (NSCLC) patients. This combination therapy demonstrated better progression-free survival and overall survival compared to chemotherapy alone.

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Programmed cell death 1 (PD-1) inhibitors are increasingly used in cancer treatment.
  • Limited domestic evidence exists for PD-1 inhibitor use in Chinese lung cancer patients.
  • Advanced, driver-gene-negative, nonsquamous NSCLC presents a specific treatment challenge.

Purpose of the Study:

  • To evaluate the efficacy and safety of PD-1 inhibitor plus chemotherapy in real-world NSCLC patients.
  • To compare treatment outcomes between combination therapy and chemotherapy alone.
  • To assess the tolerance and adverse events associated with PD-1 inhibitor combination therapy.

Main Methods:

  • Retrospective cohort study of 68 advanced driver-gene-negative nonsquamous NSCLC patients.
  • Comparison between 38 patients receiving PD-1 inhibitor plus chemotherapy and 30 receiving chemotherapy alone.
  • Analysis of disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events.

Main Results:

  • PD-1 inhibitor plus chemotherapy showed a higher ORR (52.6% vs. 30.0%) and significantly improved PFS (median 10.1 vs. 7.1 months) and OS (median 17.4 vs. 13.9 months).
  • Multivariable Cox's analyses confirmed PD-1 inhibitor plus chemotherapy as an independent predictor of prolonged PFS and OS.
  • The majority of adverse events were manageable, with common grade 3-4 events including leukopenia and neutropenia.

Conclusions:

  • PD-1 inhibitor plus chemotherapy offers superior efficacy compared to chemotherapy alone in advanced driver-gene-negative nonsquamous NSCLC.
  • The combination therapy demonstrates comparable tolerance to chemotherapy alone.
  • Real-world data supports the use of PD-1 inhibitor plus chemotherapy for this patient population.
Keywords:
driver-gene-negativeefficacynon-small-cell lung cancerprogrammed cell death 1 inhibitorsafety

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643